Cargando…
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy
Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications wi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086752/ https://www.ncbi.nlm.nih.gov/pubmed/29787423 http://dx.doi.org/10.1097/CJI.0000000000000224 |
_version_ | 1783346558970888192 |
---|---|
author | Ileana Dumbrava, Ecaterina Smith, Veronica Alfattal, Rasha El-Naggar, Adel K. Penas-Prado, Marta Tsimberidou, Apostolia M. |
author_facet | Ileana Dumbrava, Ecaterina Smith, Veronica Alfattal, Rasha El-Naggar, Adel K. Penas-Prado, Marta Tsimberidou, Apostolia M. |
author_sort | Ileana Dumbrava, Ecaterina |
collection | PubMed |
description | Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy. |
format | Online Article Text |
id | pubmed-6086752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-60867522018-08-24 Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy Ileana Dumbrava, Ecaterina Smith, Veronica Alfattal, Rasha El-Naggar, Adel K. Penas-Prado, Marta Tsimberidou, Apostolia M. J Immunother Clinical Studies Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte–associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy. Lippincott Williams & Wilkins 2018-09 2018-08-21 /pmc/articles/PMC6086752/ /pubmed/29787423 http://dx.doi.org/10.1097/CJI.0000000000000224 Text en Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government. |
spellingShingle | Clinical Studies Ileana Dumbrava, Ecaterina Smith, Veronica Alfattal, Rasha El-Naggar, Adel K. Penas-Prado, Marta Tsimberidou, Apostolia M. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy |
title | Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy |
title_full | Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy |
title_fullStr | Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy |
title_full_unstemmed | Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy |
title_short | Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy |
title_sort | autoimmune granulomatous inflammation of lacrimal glands and axonal neuritis following treatment with ipilimumab and radiation therapy |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086752/ https://www.ncbi.nlm.nih.gov/pubmed/29787423 http://dx.doi.org/10.1097/CJI.0000000000000224 |
work_keys_str_mv | AT ileanadumbravaecaterina autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy AT smithveronica autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy AT alfattalrasha autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy AT elnaggaradelk autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy AT penaspradomarta autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy AT tsimberidouapostoliam autoimmunegranulomatousinflammationoflacrimalglandsandaxonalneuritisfollowingtreatmentwithipilimumabandradiationtherapy |